FRANKLIN, Mass., July 20 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONT) announced today that it has received a U.S.
patent describing the technology for transdermal continuous glucose
monitoring. This technology details both the method and system to enhance
the permeability of skin, ultimately facilitating the continuous detection
of a body analyte, such as blood glucose. U.S. Patent No. 7,066,884
entitled, "System, Method, and Device for Non-Invasive Body Fluid Sampling
and Analysis" was issued to Sontra on June 27, 2006.
"This patent further strengthens the intellectual property portfolio
surrounding Sontra's non-invasive diagnostics, and is central in
transdermal and continuous glucose monitoring technology," stated Scott
Kellogg, Sontra's Vice President of Research and Development.
Sontra Medical Corporation's continuous non-invasive glucose monitoring
technology has significant implications in the critical care setting, as
well as home glucose testing. The continuous non-invasive glucose monitor
measures glucose diffusing through ultrasonically permeated skin for
twenty- four hours. This patent is a marked advance for Sontra, as it
describes the process for non-invasive body fluid sampling and analysis.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal
science. Sontra's SonoPrep ultra-sound mediated skin permeation technology
combined with technical competencies in transdermal drug formulation,
delivery systems, and biosensors is creating a new paradigm in transdermal
drug delivery and diagnosis. The SonoPrep technology is being developed for
several billion- dollar market opportunities, including continuous glucose
monitoring and the transdermal delivery of large molecule drugs and
vaccines. Sontra is currently marketing the SonoPrep device and procedure
tray for use with topical lidocaine to achieve rapid (within five minutes)
skin anesthesia.
This press release contains forward-looking statements, which address a
variety of subjects including, for example, the expected technological
advances and availability of the second-generation SonoPrep device, the
expected benefits and efficacy of the SonoPrep device in connection with
diagnostics, vaccine delivery, glucose monitoring and transdermal drug
delivery, Sontra's expected ability to develop, market and sell products
based on its technology, including a continuous transdermal glucose monitor
for the hospital ICU market; the expected market opportunities,
distribution and market acceptance of the SonoPrep device and technology,
the expected size of the market for the continuous transdermal glucose
monitor for the hospital ICU; and Sontra's business, research, product
development, regulatory approval, marketing and distribution plans and
strategies. Statements that are not historical facts, including statements
about our beliefs and expectations, are forward-looking statements. Such
statements are based on our current expectations and are subject to a
number of factors and uncertainties, which could cause actual results to
differ materially from those described in the forward-looking statements.
The following important factors and uncertainties, among others, could
cause actual results to differ materially from those described in these
forward-looking statements: our technology is new and we may experience
adverse results in research and development efforts, product development,
clinical trials, product evaluations, commercialization efforts, product
distribution and market acceptance; markets for our products may develop
slower than expected, or not at all; our sales cycle is lengthy and we are
still developing sales and marketing strategies which may or may not prove
effective; the SonoPrep device may not prove effective in connection with
diagnostics, vaccine delivery, glucose monitoring and/or transdermal drug
delivery; we may experience difficulties or delays in obtaining regulatory
approvals to market products resulting from development efforts or
difficulties or delays associated with sources of regulatory-approved
transdermal drugs and vaccines; failure to obtain and maintain patent
protection for discoveries or commercial limitations imposed by patents
owned or controlled by third parties would have an adverse effect on us; we
depend upon strategic partners and third-party distributors to develop,
commercialize, market and sell products based on our work; and we require
substantial additional funding to conduct research and development and to
expand commercialization, distribution and marketing activities. For
detailed information about factors that could cause actual results to
differ materially from those described in the forward-looking statements,
please refer to Sontra's filings with the Securities and Exchange
Commission, including Sontra's most recent Annual Report on Form 10-KSB.
Forward-looking statements represent management's current expectations and
are inherently uncertain. We do not undertake any obligation to update
forward-looking statements made by us.
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks
or registered trademarks of their respective owners.
Investor Relations Contacts:
Barry Marston, VP Sales & Marketing
508-530-0332
bmarston@sontra.com
Harry G. Mitchell, CFO
508-530-0311
hmitchell@sontra.com
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com/
CONTACT:
Barry Marston, Investor Relations, VP Sales &
Marketing, +1-508-530-0332, bmarston@sontra.com, or Investor
Relations, Harry G. Mitchell, CFO, +1-508-530-0311,
hmitchell@sontra.com
|
